Trials / Completed
CompletedNCT02147535
Impact of CES1 Genotype on Metabolism of Methylphenidate
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 78 (actual)
- Sponsor
- Bispebjerg Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine whether differences in the gene coding for the liver enzyme carboxylesterase 1 (CES1) means differences in the metabolism of methylphenidate, a CES1 dependent drug.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Methylphenidate | 10 mg as a single dose followed by one blood sample 3 hours post-dose |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2014-08-01
- First posted
- 2014-05-26
- Last updated
- 2014-10-13
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT02147535. Inclusion in this directory is not an endorsement.